Targeting the mTOR pathway in chromophobe kidney cancer

Journal of Cancer

Volumn 3, Issue 1, 2012, Pages 152-157

  Shuch, Brian ^a   Vourganti, Srinivas ^a   Friend, Julia C ^a   Zehngebot, Lee M ^b   Marston Linehan, W ^a   Srinivasan, Ramaprasad ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Orlando Oncology   (United States)

Author keywords

Chromophobe kidney cancer; MTOR inhibitors

Indexed keywords

BEVACIZUMAB; MAMMALIAN TARGET OF RAPAMYCIN; SUNITINIB; TEMSIROLIMUS;

ABDOMINAL MASS; ADULT; ADVANCED CANCER; ARTICLE; BIRT HOGG DUBE SYNDROME; CANCER PATIENT; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DISEASE SURVEILLANCE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FATIGUE; FEMALE; HUMAN; KIDNEY CARCINOMA; LAPAROSCOPY; LITERATURE; LIVER NODULE; LUNG METASTASIS; LUNG NODULE; MULTIPLE CYCLE TREATMENT; NEPHRECTOMY; POPULATION RESEARCH; PROTEINURIA; SIGNAL TRANSDUCTION; WEIGHT REDUCTION;

EID: 84867493277     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.4378     Document Type: Article

References (14)

1. Hasumi Y, Baba M, Ajima R, et al: Homozygous loss of BHD causes early embryonic lethality and kidney tumor development with activation of mTORC1 and mTORC2. Proc Natl Acad Sci U S A 2009;106:18722-7.
2. Molina AM, Feldman DR, Ginsberg MS, et al: Phase II trial of sunitinib in patients with metastatic non-clear cell renal cell carcinoma. Invest New Drugs 2012 Feb;30(1):335-40.
3. Plimack E, Jonasch E, Bekele B, et al: Sunitinib in papillary renal cell carcinoma (pRCC): Results from a single-arm phase II study. J Clin Oncol 2010; 28:15s.
4. Choueiri TK, Plantade A, Elson P, et al: Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol, 2008; 26:127-31.
5. Stadler WM, Figlin RA, McDermott DF, et al: Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer 2010 Mar 1;116(5):1272-80.
6. Hudes G, Carducci M, Tomczak P, et al: Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med, 2007; 356:2271-81.
7. Larkin JM, Fisher RA, Pickering LM, et al: Chromophobe renal cell carcinoma with prolonged response to sequential sunitinib and everolimus. J Clin Oncol 2011;29:e241-2.
8. Paule B, Brion N: Temsirolimus in metastatic chromophobe renal cell carcinoma after interferon and sorafenib therapy. Anticancer Res 2011;31:331-3.
9. Zardavas D, Meisel A, Samaras P, et al: Temsirolimus Is Highly Effective as Third-Line Treatment in Chromophobe Renal Cell Cancer. Case Reports in Oncology, 2011; 4:16-18.
10. Motzer RJ, Bacik J, Mariani T, et al: Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J Clin Oncol, 2002; 20:2376-81.
11. Klatte T, Han KR, Said JW, et al: Pathobiology and prognosis of chromophobe renal cell carcinoma. Urol Oncol, 2008; 26:604-9.
12. Shuch B, Belldegrun A: Re: efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. Eur Urol, 2008; 53:1085-6.
13. Yang JC, Haworth L, Sherry RM, et al: A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med, 2003; 349:427-34.
14. Baba M, Furihata M, Hong SB, et al: Kidney-targeted Birt-Hogg-Dube gene inactivation in a mouse model: Erk1/2 and Akt-mTOR activation, cell hyperproliferation, and polycystic kidneys. J Natl Cancer Inst, 2008; 100:140-54.